cystic fibrosis transmembrane conductance regulator

Elexacaftor (VX-445) 是一种囊性纤维化跨膜电导调节因子 (CFTR) 校正剂。它促进CFTR 的加工和转运，增加细胞表面CFTR 的数量。

CFTR corrector 4是一种高效且可口服的囊性纤维化跨膜电导调节剂 (CFTR)，是一种有效的 (R，R) 型活性对映体。CFTR corrector 4 可以增加细胞表面的 CFTR 水平，是用来研究囊性纤维化的潜在化合物。

Lumacaftor (VRT 826809) 是一种 CFTR 调节剂，可纠正 CFTR 蛋白的折叠和运输。它增强了 FRT 细胞中 F508del-CFTR 蛋白的成熟，EC50为100 nM。

Glibenclamide (Glyburide) 是一种具有口服活性的 ATP 敏感的 K+通道抑制剂，可研究糖尿病和肥胖。它抑制 P-糖蛋白，可直接结合并阻断 KATP 的 SUR1亚基并抑制囊性纤维化跨膜传导调节蛋白。它通过诱导膜离子通透性干扰线粒体生物能，可诱导自噬。

DNDS 是电压依赖性囊性纤维化跨膜电导调节剂 (CFTR) 的通道阻滞剂。

Ivacaftor (VX-770) 是一种 CFTR 增强剂，靶向G551D-CFTR 和F508del-CFTR 的EC50分别为100 和 25 nM。

Ataluren (PTC124) 是一种可口服的 CFTR-G542X 无义等位基因抑制剂。

Cavosonstat (N91115) 是一种口服活性 S-亚硝基谷胱甘肽还原酶(GSNOR)抑制剂，可促进囊性纤维化跨膜传导调节器(CFTR)成熟和质膜稳定。

CFTR校正剂8是一种对囊性纤维化跨膜传导调节器（CFTR）具有高效调控作用的化合物。该化合物特别用于与囊性纤维化相关的研究，这是一种主要影响肺和消化系统的遗传性疾病[1]。

BPO-27 racemate (BPO-27(racemate)) 是一种CFTR 抑制剂，IC50为8 nM。

CFTR(inh)-172 (CFTR Inhibitor-172) 是一种不依赖电压的选择性 CFTR 抑制剂，在2分钟内可逆地抑制CFTR 短路电流的Ki 值为300 nM。

GlyH-101 是一种可渗透入细胞的 CFTR 阻断剂，Ki 为1.4 uM。

Tezacaftor (VX661) 是一种小分子，可用作囊性纤维化跨膜电导调节器基因功能的校正剂。

GLPG1837 (ABBV-974) 是一种有效的 CFTR 增强剂，对其 F508del 和 G551D 的 EC50 分别为 3 nM 和 339 nM。

Nesolicaftor (PTI-428) 特异性增强囊性纤维化跨膜电导调节蛋白合成。

Icenticaftor (QBW251) 是一种具有口服活性CFTR 通道增强剂，可用于慢性阻塞性肺疾病 (COPD) 和囊性纤维化研究，对F508del 和G551D CFTR 的EC50分别为 79 和 497 nM。

CFTR corrector 2 (FDL169) 是一种新型有效的囊性纤维化跨膜电导调节因子(CFTR)调节剂，用于治疗携带 F508del 突变的囊性纤维化患者。

CFTR corrector 9是一种囊性纤维化跨膜传导调节蛋白 (CFTR)调节剂。CFTR corrector 9 可用于研究囊性纤维化 (CF) 和其他 CFTR 相关疾病。

PPQ-102 (CFTR Inhibitor) 是一种CFTR 抑制剂，可以完全抑制CFTR 氯化物电流，IC50为90 nM。

IOWH-032 (IOWH032) 是一种合成 CFTR 抑制剂，可用于研究治疗霍乱、腹泻和分泌性腹泻，在T84和CHO-CFTR 细胞实验中IC50为1.01 uM。

KM11060 是 F508del-CFTR 运输缺陷的新型校正剂，可纠正 F508del-CFTR 运输，增加质膜上功能性 CFTR 的数量。它可用于 F508del-CFTR 加工缺陷的研究和囊性纤维化治疗剂的开发。

CTP-656, a cystic fibrosis transmembrane conductance regulator (CFTR) channel activator, is used potentially for the treatment of cystic fibrosis.

(R)-Elexacaftor，Elexacaftor (Compound 1) 的对映异构体，为囊性纤维化跨膜电导调节因子（CFTR）校正剂，其针对CFTR dF508突变体的EC50值为0.29 uM。

Tezacaftor-d4 是 Tezacaftor 的氘代化合物。Tezacaftor 的 CAS 号为 1152311-62-0。VX-661 是一种小分子，可用作囊性纤维化跨膜电导调节器基因功能的校正剂。

In epididymal epithelial cells, AF-2785 inhibits cystic fibrosis transmembrane conductance regulator Cl(-) channels.

C4 Ceramide is a bioactive sphingolipid and cell-permeable analog of naturally occurring ceramides. [1] [2] [3] It inhibits IL-4 production by 16% in EL4 T cells stimulated with phorbol 12-myristate 13-acetate when used at a concentration of 10 μM. [1] C4 Ceramide is cytotoxic to SK-BR-3 and MCF-7 Adr breast cancer cells (IC50s = 15.9 and 19.9 μM, respectively). [2] C4 Ceramide also increases maturation and stability of cystic fibrosis transmembrane conductance regulator (CFTR) proteins bearing the F508 deletion (F508del) mutation, enhances cAMP-activated chloride secretion, and suppresses secretion of IL-8 in primary epithelial cells isolated from patients with cystic fibrosis.[3]

Flufenamic acid-d4 is intended for use as an internal standard for the quantification of flufenamic acid by GC- or LC-MS. Flufenamic acid is a non-steroidal anti-inflammatory drug (NSAID) and COX inhibitor (IC50s = 3 and 9.3 µM for human COX-1 and COX-2, respectively). Flufenamic acid inhibits TNF-α-induced increases in COX-2 levels and NF-κB activation in HT-29 colon cancer cells in a concentration-dependent manner. It inhibits calcium influx induced by fMLP or A23187 in human polymorphonuclear leukocytes (PMN) with IC50 values of 29 and 14 µM, respectively. Flufenamic acid also activates various ion channels, including transient receptor potential canonical 6 (TRPC6) and the large-conductance calcium-activated potassium channel (KCa1.1). It also inhibits various ion channels, including TRPC3 and the cystic fibrosis transmembrane conductance regulator (CFTR). Flufenamic acid (20 mg/kg) reduces increases in intestinal fluid secretion and intestinal barrier disruption in mice ......

Vanzacaftor 是一种囊性纤维化跨膜电导调节体（CFTR）的调节剂，用于研究囊性纤维化。

CFTR corrector 6 is a highly effective CFTR potentiator utilized in research on cystic fibrosis (CF) and related CFTR-associated disorders[1]. This potent compound exhibits potentiation activity on the Cystic Fibrosis Transmembrane conductance Regulator (CFTR), rendering it beneficial for investigations in CF and other associated conditions.

(R)-Olacaftor ((R)-VX-440)，一种对囊性纤维化 (CF) 具有研究潜力的囊性纤维化跨膜调节因子 (CFTR) 调节剂。

SRI-41315, a chemical compound, effectively addresses premature termination codons (PTCs) associated with cystic fibrosis in immortalized and primary human bronchial epithelial cells. It induces a prolonged pause at stop codons, resulting in the restoration of cystic fibrosis transmembrane conductance regulator (CFTR) expression and function. This compound achieves PTC suppression by reducing the abundance of the termination factor eRF1. Additionally, SRI-41315 synergistically enhances CFTR activity by potentiating aminoglycoside-mediated readthrough [1].

(R)-Vanzacaftor ((R)-VX-121) 为一种作用于囊性纤维化跨膜传导调节剂(CFTR)的调节剂。

GLPG2451 is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator. It effectively potentiates low temperature rescued F508del CFTR (EC50: 11.1 nM).

UCCF-029 is an activator of cystic fibrosis transmembrane conductance regulator (CFTR).

GLPG-3221 can be uesd for the treatment of cystic fibrosis.GLPG-3221 is a potent, orally active corrector of CFTR (cystic fibrosis transmembrane conductance regulator), with an EC50 of 105 nM.